Preclinical News and Research

RSS

Anacor Pharma, MMV enter agreement to develop AN3661 for malaria treatment

Anacor Pharmaceuticals announced today that it has entered into a development agreement with Medicines for Malaria Venture to develop Anacor's compound AN3661 for the treatment of malaria.

18 Mar 2011

GenSpera strengthens intellectual property for second prostate cancer drug

GenSpera, Inc. announced that its patent application, entitled "Activation of Peptide Prodrugs by HK2," has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,906,477.

17 Mar 2011

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

PsiOxus Therapeutics, Ltd. announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated with significant morbidity and mortality.

17 Mar 2011

Digna Biotech and Biotecnol to begin CT-I Phase I trial in healthy volunteers

Digna Biotech and Biotecnol announced today that the Spanish Regulatory Medicine Agency has authorized the start of a Phase I Clinical Trial in healthy volunteers for Cardiotrophin-I.

17 Mar 2011

Malaria drug shrinks, slows resistant pancreatic tumors

Dana-Farber Cancer Institute scientists report they have shrunk or slowed the growth of notoriously resistant pancreatic tumors in mice, using a drug routinely prescribed for malaria and rheumatoid arthritis.

16 Mar 2011

iTherX commences ITX-5061 Phase 1b study in patients with HCV

iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that it has commenced patient recruitment in an open-label, proof-of-concept Phase 1b study of its lead compound ITX-5061 in liver transplant patients with hepatitis C virus infection.

16 Mar 2011

Apeiron in antitumor substances deal with Cleveland Clinic

APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.

15 Mar 2011

Omeros fourth quarter net loss increases to $7.2 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2010.

15 Mar 2011

CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

Patients with earlier stage high-risk Chronic Lymphocytic Leukemia recently began receiving a new combination treatment in a Phase I/II clinical trial that researchers believe could result in a more effective therapy for this disease, Biothera announced today.

15 Mar 2011

ShangPharma fourth quarter net revenues increase 29.4% to $25.6 million

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its fourth quarter and the fiscal year ended December 31, 2010.

15 Mar 2011

InhibOx and COSMIC discoveries align to deliver full service drug discovery offering

InhibOx Ltd (spin-out of Oxford, UK) and the COSMIC Discoveries (the independent service arm of the Institute of Life Sciences, Hyderabad, India) today announce that they have formed a close strategic partnership to deliver a full service drug discovery service offering, incorporating expert computational, medicinal and synthetic chemistry design capabilities. Both commercial organizations, linked to world-leading academic institutes, have built their services on advanced proprietary science and technology. Together, they offer unique capabilities that are able to address the most demanding drug discovery challenges on behalf of biotech and pharmaceutical companies worldwide.

15 Mar 2011

New study: Two peptide agent combination might block tumor growth

A new study suggests that combining two experimental anticancer peptide agents might simultaneously block formation of new tumor blood vessels while also inhibiting the growth of tumor cells.

15 Mar 2011

Positive results from azide drug-loaded Emulsiphan preclinical toxicity study

Cornerstone Pharmaceuticals, Inc., a leader in cancer metabolism-based therapeutics, today announced encouraging results of a preclinical toxicity study of azide drug-loaded Emulsiphan nano emulsions conducted with the National Cancer Institute (NCI) under a Collaboration Agreement. Emulsiphan is Cornerstone's proprietary nanoparticle drug delivery system.

14 Mar 2011

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.

14 Mar 2011

SOM Biotech closes first financing round and files patent application

SOM Biotech, a biopharmaceutical start-up company with a business model centered on the identification and development of drug repurposing opportunities, reports significant progress on its trajectory towards pipeline development and candidate outlicensing.

14 Mar 2011

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Ardea Biosciences, Inc., a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and announced fourth quarter and full-year 2010 financial results.

11 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

American Botanical Council honors excellence in herbal medicine

The 6th Annual American Botanical Council Celebration and Awards Ceremony took place last night, honoring individuals and companies who influence the present and future of the herbal medicine movement. The ABC event is part of the annual Natural Products Expo West trade show and Nutracon scientific conference, held in Anaheim, California.

11 Mar 2011

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease.

11 Mar 2011